Search
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its … [L32853] An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity.
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It is administered as a single, one-time intravenous infusion. … [L64050,L64051] The approval covers adults and pediatric patients 8 years of age and older and was based on a statistically significant reduction in daily cornstarch intake, a surrogate endpoint, with
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalAn anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. … It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Paramethadione
go.drugbank.com/drugs/DB00617ApprovedIt is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Gepirone
go.drugbank.com/drugs/DB12184ApprovedIt was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.
Dihydroergocornine
go.drugbank.com/drugs/DB11273Approved[T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049]
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels ...